Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
- Lancaster, L.H. (Lisa H.)
- de Andrade, J.A. (Joao A.)
- Zibrak, J.D. (Joseph D.)
- Padilla, M.L. (Maria L.)
- Albera, C.
- Nathan, S.D. (Steven D.)
- Wijsenbeek-Lourens, M.S. (Marlies)
- Stauffer, J.L. (John L.)
- Kirchgaessler, K.-U. (Klaus-Uwe)
- Costabel, U.
Publication date
December 2017
DOI Publisher
European Respiratory Society (ERS)Abstract
Pirfenidone is one of two approved therapies for the treatment of idiopathic pulmonary fibrosis (IPF). Randomised controlled clinical trials an
Add to ORKG